当然，风险亦不容忽视。Infigratinib是泛FGFR1-4抑制剂，对FGFR1等的抑制可能引起高磷血症等副作用。3期试验中约有4%患者出现轻度、短暂的高磷血症。在儿科长期用药的背景下，其安全性仍需更严格的监测，监管的要求也会更严格。
"Although I am not an expert, this suggests that there needs to be some steps taken to make this area safe," Walker said.
。关于这个话题，heLLoword翻译官方下载提供了深入分析
В России ответили на имитирующие высадку на Украине учения НАТО18:04
Reporting by Chance Townsend, Caitlin Welsh, Sam Haysom, Amanda Yeo, Shannon Connellan, Cecily Mauran, Mike Pearl, and Adam Rosenberg contributed to this article.
20+ curated newsletters